{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T10:43:58Z","timestamp":1698403438748},"reference-count":31,"publisher":"Akademiai Kiado Zrt.","issue":"35","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,8,28]]},"abstract":"<jats:p><jats:italic>Bevezet\u00e9s:<\/jats:italic> A gyermekkori uveitisek kezel\u00e9s\u00e9ben 2016 \u00f3ta van\n                    lehet\u0151s\u00e9g biol\u00f3giai ter\u00e1pia alkalmaz\u00e1s\u00e1ra. Szem\u00e9szeti indik\u00e1ci\u00f3 eset\u00e9n\n                    adalimumabbal ind\u00edthat\u00f3 ter\u00e1pia, mely egy tumornekr\u00f3zisfaktor-ellenes\n                    monoklon\u00e1lis antitest. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Klinik\u00e1nk\n                    uveitisambulanci\u00e1j\u00e1n a gyermekkori uveitis miatt kezelt betegek adatainak\n                    retrospekt\u00edv feldolgoz\u00e1sa alapj\u00e1n a nem fert\u0151z\u00e9ses eredet\u0171 uveitis eset\u00e9n\n                    alkalmazott adalimumabkezel\u00e9sr\u0151l szerzett tapasztalataink \u00f6sszefoglal\u00e1sa.\n                        <jats:italic>Betegek \u00e9s m\u00f3dszerek:<\/jats:italic> Restrospekt\u00edv m\u00f3don elemezt\u00fck a\n                    Szegedi Tudom\u00e1nyegyetem Szem\u00e9szeti Klinik\u00e1j\u00e1n 2017. 01. 01. \u00e9s 2021. 05. 31.\n                    k\u00f6z\u00f6tt uveitis miatt gondozott gyermekek adatait. <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    2017 \u00e9s 2021 k\u00f6z\u00f6tt 46 uveitises gyermeket vizsg\u00e1ltunk klinik\u00e1nkon. A 23 l\u00e1ny \u00e9s\n                    23 fi\u00fagyermek \u00e1tlag\u00e9letkora 11 \u00e9v volt. K\u00f6z\u00fcl\u00fck 21 gyermek szenvedett juvenilis\n                    idiopathi\u00e1s arthritisben, 14 gyermekn\u00e9l igazol\u00f3dott infekci\u00f3, 3 gyermekn\u00e9l\n                    hematol\u00f3giai betegs\u00e9g okozta az elv\u00e1ltoz\u00e1st, 8 gyermekn\u00e9l idiopathi\u00e1s eredet\u0171\n                    volt a gyullad\u00e1s. Kr\u00f3nikus, s\u00falyos uveitis miatt 11 gyermekn\u00e9l ind\u00edtottunk\n                    biol\u00f3giai ter\u00e1pi\u00e1t az Eur\u00f3pai Gy\u00f3gyszer\u00fcgyn\u00f6ks\u00e9g enged\u00e9lye alapj\u00e1n. 3 fi\u00fagyermek\n                    \u00e9s 8 l\u00e1nygyermek r\u00e9szes\u00fclt adalimumabkezel\u00e9sben, \u00e1tlag\u00e9letkoruk 10 \u00e9v volt. 6\n                    gyermekn\u00e9l anterior, 5 gyermekn\u00e9l panuveitis indik\u00e1lta a kezel\u00e9st. Az adalimumab\n                    alkalmaz\u00e1si leirata szerint 2 \u00e9vn\u00e9l id\u0151sebb gyermekekn\u00e9l a kr\u00f3nikus, nem\n                    fert\u0151z\u00e9ses eredet\u0171 szemgyullad\u00e1s kezel\u00e9s\u00e9re alkalmazhat\u00f3, amikor a gyullad\u00e1s a\n                    szem el\u00fcls\u0151 r\u00e9sz\u00e9t \u00e9rinti. Panuveitises betegeink eset\u00e9n gyermekreumatol\u00f3gus\n                    seg\u00edts\u00e9g\u00e9t k\u00e9rt\u00fck a biol\u00f3giai ter\u00e1pia enged\u00e9lyez\u00e9s\u00e9hez.\n                        <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> A gyermekkori uveitisek \u00e9s azok ter\u00e1pi\u00e1j\u00e1nak\n                    jelent\u0151s\u00e9ge kiemelked\u0151. A szem\u00e9szeti kezel\u00e9s c\u00e9lja a gyermekek l\u00e1t\u00e1s\u00e9less\u00e9g\u00e9nek\n                    meg\u0151rz\u00e9se \u00e9s a szem\u00e9szeti sz\u00f6v\u0151dm\u00e9nyek megel\u0151z\u00e9se mellett a betegek megfelel\u0151\n                    \u00e9letmin\u0151s\u00e9g\u00e9nek biztos\u00edt\u00e1sa. Kiemelked\u0151 fontoss\u00e1g\u00fa a korai diagn\u00f3zis, a\n                    megfelel\u0151 ter\u00e1pia, a rendszeres kontrollvizsg\u00e1lat. Az adalimumab hat\u00e9konys\u00e1g\u00e1t\n                    mutatja, hogy a kezelt gyermekek jelent\u0151s sz\u00e1zal\u00e9k\u00e1n\u00e1l siker\u00fclt a teljes\n                    l\u00e1t\u00e1s\u00e9less\u00e9get el\u00e9rni, valamint a kezel\u00e9s mellett \u00fajabb szem\u00e9szeti sz\u00f6v\u0151dm\u00e9ny\n                    nem alakult ki. Orv Hetil. 2022; 163(35): 1402\u20131408.<\/jats:p>","DOI":"10.1556\/650.2022.32578","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T01:41:14Z","timestamp":1668822074000},"page":"1402-1408","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":0,"title":["A biol\u00f3giai ter\u00e1pia helye a gyermekkori uveitis ell\u00e1t\u00e1s\u00e1ban"],"prefix":"10.1556","volume":"163","author":[{"given":"Lilla","family":"Smeller","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika 6722 Szeged, Kor\u00e1nyi fasor 10\u201311., 6720 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikt\u00f3ria","family":"S\u00fcmegi","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Reumatol\u00f3giai \u00e9s Immunol\u00f3giai Klinika Szeged Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"T\u00f3th-Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika 6722 Szeged, Kor\u00e1nyi fasor 10\u201311., 6720 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Soh\u00e1r","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika 6722 Szeged, Kor\u00e1nyi fasor 10\u201311., 6720 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/BOR.0000000000000316","article-title":"Uveitis in children","volume":"28","author":"Angeles-Han ST","year":"2016","unstructured":"1 Angeles-Han ST, Rabinovich CE. Uveitis in children. Curr Opin Rheumatol. 2016; 28: 544-549.","journal-title":"Curr Opin Rheumatol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3109\/09273948.2016.1167223","article-title":"Chronic anterior uveitis in children","volume":"24","author":"2 Couto","year":"2016","unstructured":"2 Couto C, Frick MM, LaMattina K, et al. Chronic anterior uveitis in children. Ocul Immunol Inflamm. 2016; 24: 392-396.","journal-title":"Ocul Immunol Inflamm"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/0974-620X.122267","article-title":"An update","volume":"6","author":"Majumder PD","year":"2013","unstructured":"3 Majumder PD, Biswas J. Pediatric uveitis. An update. Oman J Ophthalmol. 2013; 6: 140-150.","journal-title":"Oman J Ophthalmol"},{"key":"ref3","unstructured":"4 Tugal-Tutkun I. Pediatric uveitis. J Ophthalmic Vis Res. 2011; 6: 259-69."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12348-011-0044-8","article-title":"Patterns of childhood - onset uveitis in a referral center in Turkey","volume":"2","author":"5 Ozdal","year":"2012","unstructured":"5 Ozdal PC, Sen E, Yazici A, et al. Patterns of childhood - onset uveitis in a referral center in Turkey. J Ophthalmic Inflamm Infect. 2012; 2: 13-19.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5301\/ejo.5000331","article-title":"Presumed herpetic anterior uveitis: a study with retrospective analysis of 79 cases","volume":"24","author":"6 Nalcacioglu-Y\u00fcksekkaya","year":"2014","unstructured":"6 Nalcacioglu-Y\u00fcksekkaya P, Ozdal PC, Teke MY, et al. Presumed herpetic anterior uveitis: a study with retrospective analysis of 79 cases. Eur J Ophthalmol. 2014; 24: 14-20.","journal-title":"Eur J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11882-013-0409-1","article-title":"Noninfectious immune-mediated uveitis and ocular inflammation","volume":"14","author":"7 Pan","year":"2014","unstructured":"7 Pan J, Kapur M, McCallum R. Noninfectious immune-mediated uveitis and ocular inflammation. Curr Allergy Asthma Rep. 2014; 14: 409.","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref7","unstructured":"8 Soh\u00e1r N, Skribek \u00c1, Hammer H. Visual acuity in cases of juvenile uveitis. [A l\u00e1t\u00e1s\u00e9less\u00e9g alakul\u00e1sa gyermekkori uveitis eset\u00e9ben.] Szem\u00e9szet 2011; 148: 73-76. [Hungarian]"},{"key":"ref8","unstructured":"9 Soh\u00e1r N. Pediatric uveitis. [Gyermekkori uveitisek.] Szem\u00e9szet 2017; 154: 191-198. [Hungarian]"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1517\/14656566.2013.816677","article-title":"Overview and recent developments in the medical management of paediatric uveitis","volume":"14","author":"10 Pilly","year":"2013","unstructured":"10 Pilly B, Heath G, Tschuor P, et al. Overview and recent developments in the medical management of paediatric uveitis. Expert Opin Pharmacother. 2013; 14: 1787-1795.","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"11 Biester","year":"2007","unstructured":"11 Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007; 91: 319-324.","journal-title":"Br J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/BOR.0000000000000723","article-title":"Update on noninfectious uveitis in children and its treatment","volume":"32","author":"12 Maccora","year":"2020","unstructured":"12 Maccora I, Sen E, Ramanan AV. Update on noninfectious uveitis in children and its treatment. Curr Op Rheumatol. 2020; 32: 395-402.","journal-title":"Curr Op Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13 G\u00e9hl Zs, Szepessy Zs, Nagy ZZs. Ophthalmic use of TNF\u03b1 inhibitor: adalimumab treatment in uveitis. [A TNF\u03b1-g\u00e1tl\u00f3 szem\u00e9szeti alkalmaz\u00e1sa: adalimumabkezel\u00e9s uveitisben.] Orv Hetil. 2021; 162: 1370-1375. [Hungarian]","DOI":"10.1556\/650.2021.32188"},{"key":"ref13","unstructured":"14 European Medicines Agency. Humira (adalimumab). EU summary of product characteristics, 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf [accessed: January 25, 2021]."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"15 Ramanan","year":"2017","unstructured":"15 Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017; 376: 1637-1646.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"16 Saurenmann","year":"2006","unstructured":"16 Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006; 45: 982-989.","journal-title":"Rheumatology"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Kiss J, Ga\u00e1l V, Ny\u00fal Z, et al. Clinical features and therapy of uveitis in childhood. [A gyermekkori uveitis klinikai jellemz\u0151i \u00e9s ter\u00e1pi\u00e1ja.] Orv Hetil. 2019; 160: 1335-1339. [Hungarian]","DOI":"10.1556\/650.2019.31459"},{"key":"ref17","unstructured":"18 Doh\u00e1n J. Uveitis and treatment in childhood. [Gyermekkori uveitisek \u00e9s kezel\u00e9s\u00fck.] Orvosk\u00e9pz\u00e9s 2014; 89: 39-41. [Hungarian]"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF\u03b1 agents","volume":"149","author":"19 Saurenmann","year":"2006","unstructured":"19 Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF\u03b1 agents. J Pediatr. 2006; 149: 833-836.","journal-title":"J Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE trial)","volume":"15","author":"20 Ramanan","year":"2014","unstructured":"20 Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE trial). Trials 2014; 15: 14.","journal-title":"Trials"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"21 Durrani","year":"2004","unstructured":"21 Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004; 88: 1159-1162.","journal-title":"Br J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/ICU.0000000000000562","article-title":"Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics","volume":"30","author":"22 Thomas","year":"2019","unstructured":"22 Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019; 30: 138-150.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"23 Jabs","year":"2000","unstructured":"23 Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130: 492-513.","journal-title":"Am J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"24 Jaffe","year":"2016","unstructured":"24 Jaffe GJ, Dick AD, Br\u00e9zin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016; 375: 932-943.","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma M","year":"2015","unstructured":"25 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-\u03b1 therapy in uveitis. Surv Ophthalmol. 2015; 60: 575-589.","journal-title":"Surv Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Beny\u00f3 F, Farkas A, Horv\u00e1th H, et al. Systemic biological treatment in ophthalmology. [Biol\u00f3giai ter\u00e1pia sziszt\u00e9m\u00e1s alkalmaz\u00e1sa a szem\u00e9szetben.] Orv Hetil. 2019; 160: 1744-1750. [Hungarian]","DOI":"10.1556\/650.2019.31552"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/09273948.2016.1158277","article-title":"Evolving \"diagnostic\" criteria for axial spondyloarthritis in the context of anterior uveitis","volume":"24","author":"27 Rosenbaum","year":"2016","unstructured":"27 Rosenbaum JT. Evolving \"diagnostic\" criteria for axial spondyloarthritis in the context of anterior uveitis. Ocul Immunol Inflamm. 2016; 24: 445-449.","journal-title":"Ocul Immunol Inflamm"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"28 Markomichelakis","year":"2004","unstructured":"28 Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004; 138: 648-650.","journal-title":"Am J Ophthalmol"},{"key":"ref28","unstructured":"29 Fodor M, Poly\u00e1k-P\u00e1sztor D, P\u00e1sztor O, et al. The impact of adalimumab in the treatment of non-infectious uveitis. [Az adalimumab jelent\u0151s\u00e9ge a nem fert\u0151z\u00e9ses eredet\u0171 uveitisek kezel\u00e9s\u00e9ben.] Szem\u00e9szet 2020; 157: 62-68. [Hungarian]"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ophtha.2019.08.031","article-title":"Long-term out-comes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"127","author":"30 Al-Janabi","year":"2020","unstructured":"30 Al-Janabi A, El Nokrashy A, Sharief L, at al. Long-term out-comes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 2020; 127: 410-416.","journal-title":"Ophthalmology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE Trial","volume":"207","author":"31 Horton","year":"2019","unstructured":"31 Horton S, Jones AP, Guly C, al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE Trial. Am J Ophthalmol. 2019; 207: 170-174.","journal-title":"Am J Ophthalmol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/35\/article-p1402.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/35\/article-p1402.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/35\/article-p1402.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T14:57:30Z","timestamp":1698332250000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/35\/article-p1402.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":31,"journal-issue":{"issue":"35"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32578","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]}}}